Literature DB >> 6629368

Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.

R H Riddell, H Goldman, D F Ransohoff, H D Appelman, C M Fenoglio, R C Haggitt, C Ahren, P Correa, S R Hamilton, B C Morson.   

Abstract

Assessment of epithelial dysplasia in ulcerative colitis has been hindered by inconsistencies in and disagreements about nomenclature and interpretation. To resolve these issues, pathologists from ten institutions participated in three exchanges of multiple slides and, following each exchange, in discussions of the results. A classification system for the epithelial changes that occur in ulcerative colitis was developed, which should be applicable to other forms of inflammatory bowel disease as well. The classification makes use of standardized terminology, addresses specific problem areas, and offers practical solutions. The reproducibility of the system was studied by means of examinations of both inter- and intra-observer variations. The clinical implications of the findings were incorporated into suggestions for patient management. The basis of the classification is that the term "dysplasia" is reserved for epithelial changes that are unequivocally neoplastic and may therefore give rise directly to invasive carcinoma. Specimens are categorized as negative, indefinite, or positive for dysplasia. The negative category includes all inflammatory and regenerative lesions and indicates that only continued regular surveillance is required. The indefinite category is applied to epithelial changes that appear to exceed the limits of ordinary regeneration but are insufficient for an unequivocal diagnosis of dysplasia or are associated with other features that prevent such unequivocal diagnosis. Clinically, it indicates that early repeat biopsy is often required to assess the changes more accurately. The positive category is divided into two subcategories: 1) high-grade dysplasia, for which colectomy should be strongly considered after confirmation of the diagnosis, and 2) low-grade dysplasia, which also requires confirmation and early repeat biopsy or colectomy, depending on other findings.

Entities:  

Mesh:

Year:  1983        PMID: 6629368     DOI: 10.1016/s0046-8177(83)80175-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  366 in total

Review 1.  Gastric epithelial dysplasia.

Authors:  G Y Lauwers; R H Riddell
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

2.  ACP. Best Practice No 155. Guidelines for handling oesophageal biopsies and resection specimens and their reporting.

Authors:  N B Ibrahim
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

3.  Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis.

Authors:  S N Andersen; T O Rognum; A Bakka; O P Clausen
Journal:  Mol Pathol       Date:  1998-12

4.  Barrett's esophagus: is dysplasia a reliable marker in surveillance after endoscopic treatment?

Authors:  M A Ortner
Journal:  Curr Gastroenterol Rep       Date:  2001-10

Review 5.  Cancer surveillance in inflammatory bowel disease.

Authors:  C N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  1999-12

6.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

7.  [Barrett esophagus: epidemiology, incidence of carcinoma, need for screening].

Authors:  R Arnold; M Wied
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

8.  Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus.

Authors:  Pascual Parrilla; Luisa F Martínez de Haro; Angeles Ortiz; Vicente Munitiz; Joaquín Molina; Juan Bermejo; Manuel Canteras
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

9.  p53 antibodies, metallothioneins, and oxidative stress markers in chronic ulcerative colitis with dysplasia.

Authors:  Hala E Hamouda; Soha S Zakaria; Saber A Ismail; Mahmoud A Khedr; Wael W Mayah
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

10.  [Preneoplasias of the large intestine].

Authors:  F P Gall
Journal:  Langenbecks Arch Chir       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.